Dr. Loeb on the Results of Active Surveillance for Prostate Cancer

Stacy Loeb, MD
Published: Monday, Aug 28, 2017



Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.

Of the patients who could be considered candidates for active surveillance, one-fifth of those patients had higher Decipher scores, indicating a greater risk of aggressive disease, states Loeb. However, there were patients with intermediate-risk disease who had low Decipher scores.

Now that there are more testing options, patients do not have to rely on one biopsy test, explains Loeb. There are imaging and genomic tests that can give a patient more data and help determine if they are candidates for active surveillance.
 
SELECTED
LANGUAGE


Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.

Of the patients who could be considered candidates for active surveillance, one-fifth of those patients had higher Decipher scores, indicating a greater risk of aggressive disease, states Loeb. However, there were patients with intermediate-risk disease who had low Decipher scores.

Now that there are more testing options, patients do not have to rely on one biopsy test, explains Loeb. There are imaging and genomic tests that can give a patient more data and help determine if they are candidates for active surveillance.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x